UK Approves Oral Wegovy Pill for Weight Management, Boosting Novo Nordisk
On June 11, 2026, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved Novo Nordisk's oral Wegovy (semaglutide) pill—the first oral GLP-1 receptor agonist—for weight management in adults with obesity or overweight with related health conditions. Based on Phase 3 OASIS 4 trial data, the approval expands Novo Nordisk's obesity portfolio, reinforcing its leadership. Berenberg analysts raised their price target, while the stock saw modest gains.
Cross-source coverage
Wire timeline
Is Novo Nordisk (NVO) One of the Best Low Volatility Stocks to Buy Under $50?
Novo Nordisk A/S (NYSE: NVO) is highlighted as one of the best low-volatility stocks under $50 following the June 11, 2026, UK MHRA approval of its Wegovy oral pill for weight management. The pill is a first-of-its-kind GLP-1 receptor agonist alternative to injectables, approved for adults with obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related conditions. Berenberg lowered its price target to DKK 400 but maintained a Buy rating. The article notes Novo Nordisk's focus on diabetes and obesity care, including GLP-1, insulin, and biopharmaceuticals. It also mentions that while NVO is a potential investment, other AI stocks may offer better upside. The stock saw a modest increase of 0.90% on the trading day.
Yahoo FinanceIs Novo Nordisk (NVO) One of the Best Low Volatility Stocks to Buy Under $50?
The article reports that Novo Nordisk's Wegovy oral pill has been approved by the UK's MHRA as the first daily GLP-1 treatment for weight management in adults with obesity or overweight with weight-related conditions. The approval allows patients to choose an oral alternative to injectable treatments. The piece also notes Berenberg lowered Novo Nordisk's price target to DKK 400 but maintained a Buy rating, and discusses the stock's low volatility profile under $50. The article is framed as an investment analysis within a list of low volatility stocks, with a promotional section for a separate AI stock report.
Yahoo FinanceNovo Nordisk Strengthens Weight-Loss Leadership with UK Approval of Oral Wegovy
Novo Nordisk A/S (NYSE:NVO) received UK regulatory approval from the MHRA for an oral version of its weight-loss drug Wegovy (semaglutide), offering a non-injectable alternative for adults with obesity or overweight with related health conditions. The approval is based on the OASIS 4 Phase 3 trial. Concurrently, Berenberg raised its price target for NVO to DKK 325, maintaining a Buy rating. This expands Novo Nordisk's obesity portfolio, which already includes injectable Wegovy and Ozempic, reinforcing its leadership in the weight-loss drug market. The article was published on Yahoo Finance on June 24, 2026.
Yahoo FinanceNovo Nordisk Strengthens Weight-Loss Leadership with Oral Wegovy Approval in UK
Novo Nordisk A/S (NYSE:NVO) received UK MHRA approval for an oral version of its weight-loss drug Wegovy, offering a non-injectable GLP-1 receptor agonist option for adults with obesity or overweight plus related health conditions. The approval, based on the OASIS 4 Phase 3 trial, expands Novo Nordisk's obesity portfolio alongside injectable Wegovy, Ozempic, and oral semaglutide. Berenberg raised its price target for NVO shares to DKK 325 from DKK 300, maintaining a Buy rating. The article positions Novo Nordisk as a leader in the weight-loss drug market, though it notes that certain AI stocks may offer better investment opportunities.
Yahoo FinanceNovo Nordisk (NVO) Identified as Top Longevity and Anti-Aging Stock, UK Approves Wegovy Pill
Novo Nordisk A/S (NYSE: NVO) is featured among the best longevity and anti-aging stocks due to its expanding portfolio of GLP-1 therapies. On June 17, Berenberg analyst Kerry Holford raised the price target to DKK 325 from DKK 300 and maintained a Buy rating. Additionally, on June 11, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved the Wegovy pill as the first oral GLP-1 receptor agonist for weight management in adults with obesity or overweight and related medical conditions, based on Phase 3 OASIS 4 trial data. Founded in 1923 and headquartered in Bagsværd, Denmark, Novo Nordisk focuses on treating chronic conditions like diabetes and obesity, which also addresses metabolic and cardiovascular diseases affecting lifespan. The article also notes that while NVO has potential, certain AI stocks may offer greater upside.
Yahoo Finance